Cargando…

Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis

OBJECTIVE: To investigate overnight variations in absolute values and patterns of cytokines including interleukin 6 (IL6) and tumour necrosis factor α (TNFα) in rheumatoid arthritis (RA), and to relate any changes to those occurring in blood cortisol. METHODS: A total of 16 people (8 female) with ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perry, M G, Kirwan, J R, Jessop, D S, Hunt, L P
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2009
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2596304/ https://www.ncbi.nlm.nih.gov/pubmed/18375536 http://dx.doi.org/10.1136/ard.2007.086561

Ejemplares similares

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study
por: Song, Yeo-Jin, et al.
Publicado: (2022)

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade
por: van Kuijk, A W R, et al.
Publicado: (2009)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis
por: Low, Audrey S L, et al.
Publicado: (2017)

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis
por: Klaasen, R., et al.
Publicado: (2012)

Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis
por: Kaczyński, Tomasz, et al.
Publicado: (2019)

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis
por: Wijbrandts, C A, et al.
Publicado: (2008)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment
por: Tan, Rachael J L, et al.
Publicado: (2010)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis
por: Takasugi, Koji, et al.
Publicado: (2006)

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
por: Harrison, M J, et al.
Publicado: (2008)

Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
por: Keystone, E C, et al.
Publicado: (2008)

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
por: Winthrop, K L, et al.
Publicado: (2016)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
por: Schoels, Monika M, et al.
Publicado: (2013)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
por: Finckh, A, et al.
Publicado: (2010)

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis
por: Druce, Katie L, et al.
Publicado: (2018)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database
por: Thiele, Katja, et al.
Publicado: (2022)

Characterization and Function of Tumor Necrosis Factor and Interleukin‐6–Induced Osteoclasts in Rheumatoid Arthritis
por: Yokota, Kazuhiro, et al.
Publicado: (2021)

Socioeconomic variation in colon cancer tumour factors associated with poorer prognosis
por: Lyratzopoulos, G, et al.
Publicado: (2003)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
por: Buttgereit, Frank, et al.
Publicado: (2013)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis
por: Wang, Fang, et al.
Publicado: (2012)

Inhibitory effects of bisbenzylisoquinolines on synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha
por: Seow, W. Kim, et al.
Publicado: (1993)

Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
por: Robak, T, et al.
Publicado: (1998)

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers
por: Di Minno, Matteo Nicola Dario, et al.
Publicado: (2014)

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
por: Stouten, Veerle, et al.
Publicado: (2021)

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
por: Emery, P, et al.
Publicado: (2008)

Synovial expression of IL-15 in rheumatoid arthritis is not influenced by blockade of tumour necrosis factor
por: Ernestam, Sofia, et al.
Publicado: (2006)

Interstitial lung disease in rheumatoid arthritis: incidence, prevalence and related drug prescriptions between 2007 and 2020
por: Albrecht, Katinka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v9o620nrt0j237squchdm35dtc